alexa Hypereosinophilic syndrome | Russian Federation| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Hypereosinophilic Syndrome

  • Hypereosinophilic syndrome

    Hypereosinophilic syndrome

    Hypereosinophilic (hy-per-ee-o-SIN-o-phil-ik) disorder (HES) alludes to a gathering of blood issue that happen when you have high quantities of eosinophils — white platelets that assume an essential part in your invulnerable framework. After some time, these high quantities of eosinophils enter different tissues, creating aggravation and in the end harming your organs, most ordinarily focusing on the skin, lung, heart, blood and sensory system. Hypereosinophilic disorder can get to be life-undermining if not treated.

  • Hypereosinophilic syndrome

    Disease Symptoms
    HES can happen at any age, in spite of the fact that it is more basic in grown-ups. Individuals with HES may experience the ill effects of a wide assortment of indications, contingent on which parts of the body are influenced. These manifestations include:Skin rashes, for example, urticaria or angioedema, Dizziness, Memory misfortune or disarray, Cough, Shortness of inhale, Fatigue, Fever, Mouth wounds.

  • Hypereosinophilic syndrome

    Disease Treatment
    The goal of HES treatment is to reduce eosinophil levels in the blood and tissues, thereby preventing tissue damage–especially in the heart. Standard HES treatment includes glucocorticosteroid medications such as prednisone, and chemotherapeutic agents such as hydroxyurea, chlorambucil and vincristine. Interferon-alpha may also be used as a treatment. This medication must be administered by frequent injections. Research is uncovering new treatment therapies for HES.

  • Hypereosinophilic syndrome

    Patients were negative for the FIP1L1–PDGFRA fusion gene and required prednisone monotherapy, 20 to 60 mg per day, to maintain a stable clinical status and a blood eosinophil count of less than 1000 per microliter. Patients received either intravenous mepolizumab or placebo while the prednisone dose was tapered.

Expert PPTs
Speaker PPTs

High Impact List of Articles

Conference Proceedings